Investigational Site Number :1560008

Beijing 100142

1 studies enrolling now · 4 studies all time

What they study most

Breast Cancer, Immunoglobulin G4 Related Disease, Multiple Sclerosis

Studies at this site

• A 52-week Study of Rilzabrutinib Efficacy and Safety Compared to Placebo in Adults Diagnosed With IgG4-related Disease — Recruiting now
• Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis — Running, not enrolling
• Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressive Multiple Sclerosis — Running, not enrolling
• Amcenestrant (SAR439859) Plus Palbociclib as First Line Therapy for Patients With ER (+) HER2(-) Advanced Breast Cancer — Stopped early